[{"id":"a5794ed7-ec20-4c8e-af55-9e059e2c03e3","acronym":"RASolute 302","url":"https://clinicaltrials.gov/study/NCT06625320","created_at":"2025-02-25T14:19:38.953Z","updated_at":"2025-02-25T14:19:38.953Z","phase":"Phase 3","brief_title":"Phase 3 Study of RMC-6236 in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)","source_id_and_acronym":"NCT06625320 - RASolute 302","lead_sponsor":"Revolution Medicines, Inc.","biomarkers":" RAS","pipe":" | ","alterations":" RAS mutation","tags":["RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • leucovorin calcium • daraxonrasib (RMC-6236)"],"overall_status":"Recruiting","enrollment":" Enrollment 460","initiation":"Initiation: 10/16/2024","start_date":" 10/16/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-17"},{"id":"dc418061-81ed-44f9-ba51-9700e1510d92","acronym":"","url":"https://clinicaltrials.gov/study/NCT06128551","created_at":"2023-11-13T16:14:48.821Z","updated_at":"2024-07-02T16:34:25.613Z","phase":"Phase 1","brief_title":"Study of RMC-6291 in Combination With RMC-6236 in Participants With Advanced KRAS G12C Mutant Solid Tumors","source_id_and_acronym":"NCT06128551","lead_sponsor":"Revolution Medicines, Inc.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e daraxonrasib (RMC-6236) • elironrasib (RMC-6291)"],"overall_status":"Recruiting","enrollment":" Enrollment 210","initiation":"Initiation: 11/14/2023","start_date":" 11/14/2023","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2024-06-17"},{"id":"f9c11a75-6761-45e0-ad62-a2ea23c4eb7f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05379985","created_at":"2022-05-18T11:57:02.736Z","updated_at":"2024-07-02T16:35:17.915Z","phase":"Phase 1","brief_title":"Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","source_id_and_acronym":"NCT05379985","lead_sponsor":"Revolution Medicines, Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • RAS mutation • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • RAS mutation • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e daraxonrasib (RMC-6236)"],"overall_status":"Recruiting","enrollment":" Enrollment 474","initiation":"Initiation: 05/31/2022","start_date":" 05/31/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-02-23"}]